Original article RHEUMATOLOGY
|
|
- Bernard Dalton
- 5 years ago
- Views:
Transcription
1 RHEUMATOLOGY Rheumatology 2013;52: doi: /rheumatology/kes365 Advance Access publication 22 December 2012 Original article The effects of rituximab therapy on released interferon-c levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection Yi-Ming Chen 1,2,3, Hsin-Hua Chen 1,3, Kuo-Lung Lai 1,3, *, Wei-Ting Hung 1,3, *, Joung-Liang Lan 1,3,4 and Der-Yuan Chen 1,3,5 Abstract Objective. To investigate the influence of rituximab therapy on released IFN-g levels in the QuantiFERON- TB-Gold In-Tube (QFT-GIT) assay among RA patients of different Mycobacterium tuberculosis infection status. Methods. Change in levels of released IFN-g in the QFT-GIT assay was evaluated in RA patients who had received 1 year of rituximab treatment. A tuberculin skin test was performed using the Mantoux method and the QFT-GIT assay was performed by measuring IFN-g levels in whole blood treated with tuberculosis (TB)-specific antigens. Results. Among 56 patients, 43 patients were presumed to be without latent TB infection (LTBI), 7 patients had LTBI and 6 patients had anti-tnf-associated TB. During the 1-year period of rituximab therapy, no patient developed active TB or had QFT-GIT conversion. No significant change in released IFN-g levels on QFT-GIT assay after 1-year rituximab therapy was observed in patients with LTBI [3.39 (1.21) vs 2.47 (0.82) IU/ml] or in those with anti-tnf-associated TB [1.06 (0.22) vs 0.87 (0.39) IU/ml]. Rituximab did not inhibit TB antigen-stimulated IFN-g production ex vivo. The frequency of circulating CD19 + B cells was significantly decreased [8.56 (0.84) vs 1.52 (0.44)%, P < 0.001], paralleling the decrease in RF titre [318.5 (76.0) vs (32.1) IU/ml, P < 0.001] and DAS28 [6.49 (0.13) vs 4.59 (0.14), P < 0.001] after 1 year of rituximab therapy. However, there was no significant change in the frequency of CD3 + T cells after rituximab therapy. Conclusion. No occurrence of active TB or QFT-GIT conversion was observed in patients receiving 1 year of rituximab therapy. No significant effect of rituximab therapy on IFN-g release levels was observed in patients with LTBI and with anti-tnf-a-associated TB. Rituximab may be an alternative therapeutic agent for these patients. Key words: rituximab, interferon-g, QuantiFERON-TB-Gold In-Tube assay, tuberculosis, rheumatoid arthritis, TNF-a inhibitors. CLINICAL SCIENCE 1 Faculty of Medicine and 2 Institute of Clinical Medicine, National Yang-Ming University, Taipei, 3 Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, 4 Division of Immunology and Rheumatology, China Medical University Hospital, Taichung and 5 Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan. Submitted 9 July 2012; revised version accepted 25 October Correspondence to: Der-Yuan Chen, Taichung Veterans General Hospital, No. 160, Sec.3, Taichung-Kang Road, Taichung 40705, Taiwan. dychen@vghtc.gov.tw *Kuo-Lung Lai and Wei-Ting Hung contributed equally to this study. Introduction An increased prevalence of active tuberculosis (TB) has been reported in RA patients [1], and the risk of active TB is even higher for those receiving anti-tnf-a therapy [2 4]. Guidelines have recommended that effective TB screening should be routinely carried out and prophylactic therapy initiated before starting anti-tnf-a therapy if latent TB infection (LTBI) exists [5, 6]. However, active! The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please journals.permissions@oup.com
2 Yi-Ming Chen et al. TB may occur in RA patients despite prophylactic therapy because of isoniazid resistance or inadequate chemoprophylaxis [7, 8]. It is clinically challenging to manage active RA patients with anti-tnf-associated TB. It is well known that Th1-mediated immunity plays an important role in the response to Mycobacterium tuberculosis infection [9, 10], and T cells as well as macrophages secrete pro-inflammatory cytokines such as IFN-g and TNF-a to defend against M. tuberculosis infection [11, 12]. Rituximab, a monoclonal antibody directed against B-cell marker CD20, has been shown to be effective in RA patients with an inadequate response to anti-tnf-a therapy [13, 14]. The safety profile of extensive use of rituximab in non-hodgkin s lymphoma suggests no increase in the risk of active TB [15], and no active TB was reported in clinical trials of rituximab in RA patients [14, 16]. Furthermore, some case reports have noted that rituximab has been used safely in RA patients with anti-tnf-associated TB [17]. Jung et al. [18] also reported a patient with active RA and a past history of pulmonary TB in whom rituximab monotherapy resulted in a significant reduction in RA activity without adversely affecting the pulmonary lesion. We therefore speculate that rituximab may not increase the same theoretical concerns as TNF-a inhibitors regarding LTBI reactivation in RA patients. In a survey conducted by the Emerging Infections Network (EIN), however, rituximab therapy was found to be associated with active TB in three cases [19]. There is emerging evidence that B cells might play an important role in the containment of M. tuberculosis. Ulrichs et al. [20] showed that B cells are present in active follicle-like centres resembling secondary lymphoid organs that are located on the outer portion of granulomas in TB-infected lung tissue. Maglione et al. [21] demonstrated that B cells have a role in host defence against M. tuberculosis infection, and B cell / mice have enhanced susceptibility to TB infection. Based on these observations, there still exists the possibility that rituximab therapy has the potential to increase active TB disease. However, there is currently no recommendation for LTBI screening before rituximab therapy [22]. The major aim of this longitudinal study was to observe the safety profile of rituximab therapy with regard to the risk of TB and to investigate whether the released IFN-g levels in QuantiFERON-TB-Gold In-Tube (QFT-GIT) assay were affected by 1 year of rituximab therapy in 56 active RA patients of different M. tuberculosis infection status. In addition, we investigated the ex vivo effects of rituximab on IFN-g response to TB-specific antigens. DAS (DAS28) [25], and active disease status was defined as DAS28 >3.2. Therapeutic response was evaluated 6 months after anti-tnf-a therapy, according to the European League Against Rheumatism (EULAR) response criteria [26]. Patients were categorized into nonresponders who had either DAS28 of <1.2 or a DAS28 at 6 months of 55.1 [26]. After anti-tnf-a therapy, rituximab therapy was initiated in 21 (37.5%) patients who were non-responders, 29 (51.8%) patients who had intolerance due to skin reactions and 6 (10.7%) patients who had anti-tnf-associated TB with completion of anti-tubercular therapy (Fig. 1). All enrolled subjects were prescribed fixed-dose treatment with rituximab (1000 mg twice with a 14-day interval) at 6-monthly intervals for a 1-year period. To prevent infusion reactions, methylprednisolone 100 mg was given intravenously before starting rituximab infusion. Their combined medications included oral MTX and prednisolone. The Clinical Research Ethics Committee at our hospital (Taichung Veterans General Hospital, Taiwan) approved this study (ML21738/S08092) and each participant s written consent was obtained according to the Declaration of Helsinki. Tuberculin skin test and QFT-GIT assay All patients were evaluated before anti-tnf-a therapy using a standardized interview, chest radiographs, tuberculin skin test (TST) and QFT-GIT assay. Blood was drawn for the QFT-GIT assay, followed by TST using the Mantoux method, which was performed by intradermal injection of 2 tuberculin units of PPD RT-23 (Staten FIG. 1Flow chart of enrolled RA patients before and after rituximab therapy. Methods Study population Fifty-six patients with active RA [23] who had received anti-tnf-a therapy were enrolled from Taichung Veterans General Hospital in Taiwan where TB was prevalent with a notification rate of 74.6/ in 2002 [24]. The disease activity of RA was assessed by the 28-joint Flow chart shows the distribution of results of TST and QFT-GIT in 56 patients with RA before and after rituximab therapy. Six patients developed active TB after anti-tnf-a therapy. INHP: isoniazid prophylaxis; patients were presumed to have LTBI, if they had concordant positive TST/QFT-GIT results, and those with concordant negative TST/QFT-GIT results were presumed to be without LTBI
3 Rituximab effect on released IFN-c levels in RA Serum Institute, Denmark). If the induration diameter was 55 mm, the result was defined as positive TST [27]. The QFT-GIT assay was performed according to the manufacturer s instructions (Cellestis Ltd, Victoria, Australia). The QFT-GIT results were defined as positive if the IFN-g level was IU/ml in TB-specific antigen (early secreted antigenic target-6, culture filtrate protein-10 and T7.7)-stimulated wells after subtracting the level of the nil well according to the manufacturer s recommendation. QFT-GIT conversion was defined as baseline IFN-g <0.35 IU/ml and follow-up IFN-g IU/ml. Because there is no gold standard for diagnosis of LTBI, we presumed subjects to have LTBI if they had concordant positive TST/QFT-GIT results, and those with concordant negative TST/QFT-GIT results were presumed to have no LTBI. For LTBI-positive patients receiving anti-tnf-a therapy, isoniazid prophylactic therapy was offered for 9 months before rituximab therapy was prescribed. All patients received examination using the QFT-GIT assay before (at least 4 weeks after discontinuation of TNF-a inhibitors) and at the 12th month of rituximab therapy to evaluate its effects on released IFN-g levels in the QFT-GIT assay. Ex vivo effects of rituximab on released IFN-g levels in the QFT-GIT assay To explore ex vivo effects of rituximab on IFN-g production in the QFT-GIT assay, we examined the changes in the released IFN-g levels from whole blood stimulated with TB-specific antigens. Whole-blood samples were obtained from eight RA patients with QFT-GIT-positive result and five patients with active TB. Briefly, 1 ml of whole blood was incubated with 1mg of TB-specific antigens (ESAT-6, CFP-10 and T7.7) and rituximab (Roche Ltd, Basel, Switzerland) at concentrations of 0.1, 1 or 10 mg/ml for 20 h at 37 C, a method modified from one previous report [28]. The levels of supernatant IFN-g were compared with those in samples incubated without rituximab. Determination of levels of RF-IgM, CRP and circulating frequencies of B cells and T cells Levels of RF-IgM and CRP were measured by nephelometry (Dade Behring Inc., Newark, DE, USA). A positive result for RF-IgM was defined as a concentration >15 IU/ml; The frequencies of circulating CD19 + B cells and CD3 + T cells were measured before and at the 12th month of rituximab therapy using flow cytometry analysis. Briefly, the frequencies of circulating B cells and T cells were enumerated following standard cell surface staining techniques using phycoerythrin cyanin 7 (PE-Cy7)-conjugated CD19 and phycoerythrin-texas Red Õ -X (ECD)-conjugated CD3 (Beckman Coulter Inc., CA, USA), respectively. Lymphocytes were gated on the basis of forward- and side-scatter properties and counts of at least events were analysed. The results were analysed using CXP software (Beckman Coulter). Statistical analysis Results are presented as the mean (S.D.) or mean (S.E.M.) unless specified otherwise. For comparison of IFN-g released levels, the frequencies of circulating B cells and T cells, DAS28 and serum levels of RF-IgM as well as CRP before and after 1-year rituximab therapy during follow-up, the Wilcoxon signed rank test was employed. P < 0.05 was considered statistically significant. Results Demographic data, clinical characteristics and results of TST and QFT-G assay As illustrated in Table 1, all RA patients had active disease [mean (S.D.) DAS (0.98) and range ] before starting rituximab therapy. Among the RA patients who did not develop active TB after anti-tnf-a therapy, 43 patients were presumed to be without LTBI, whereas 7 patients were presumed to have LTBI. There were no significant differences in age at entry, percentage of females, proportion of patients with BCG vaccination, positive rate of RF antibodies, DAS28, daily dosage of CSs or proportion of used MTX among RA patients without LTBI, with LTBI and with anti-tnf-a-associated TB. Among six RA patients with anti-tnf-associated TB before rituximab therapy, three (50%) had extrapulmonary involvement, including miliary (two) and pleura involvement (one). Change in IFN-g release levels in RA patients undergoing rituximab therapy During 1 year of rituximab therapy, no patient developed active TB disease or had QFT-GIT conversion. After 1 year of rituximab therapy, there were no significant changes in IFN-g release levels of whole blood treated with TB-specific antigens in RA patients without LTBI [mean (S.E.M.) 0.13 (0.03) vs 0.10 (0.03) IU/ml], in those with LTBI [3.39 (1.21) vs 2.47 (0.82) IU/ml] or in those with recent TB [1.06 (0.22) vs 0.87 (0.39) IU/ml] (Fig. 2A). There were no significant differences in the change of released IFN-g levels between patients with inadequate response and those with intolerance to anti-tnf-a therapy. Change in levels of circulating T cells as well as B cells, serum levels of RF and CRP, and disease activity in RA patients undergoing rituximab therapy After 1 year of rituximab therapy for all RA patients, the frequencies of circulating CD19 + B cells were significantly decreased [mean (SEM) 8.56 (0.84)% vs 1.52 (0.44)%, P < 0.001], paralleling the decrease in the titres of RF [318.5 (76.0) vs (32.1) IU/ml, P < 0.001], serum levels of CRP [2.81 (0.32) vs 0.82 (0.11) mg/dl, P < 0.001] and DAS28 [6.49 (0.13) vs 4.59 (0.14), P < 0.001]. As shown in Fig. 2, the frequency of circulating CD19 + B cells, RF titre and serum levels of CRP and DAS28 were significantly decreased after 1 year of rituximab therapy in 43 LTBI-negative patients, 7 LTBI-positive patients and 6 patients with anti-tnf-associated TB. However, there were no significant changes in the frequencies of 699
4 Yi-Ming Chen et al. TABLE 1 Demographic data and laboratory findings of RA patients of different M. tuberculosis infection status before starting rituximab therapy Without developing active TB LTBI ( ) (n = 43) LTBI (+) (n =7) Anti-TNF-associated TB [2 LTBI ( ) and 4 LTBI (+)] (n =6) Age at entry, years 52.5 (12.0) 51.6 (12.4) 53.5 (9.5) Female, n (%) 39 (90.7) 5 (71.4) 5 (83.3) Disease duration, years 7.4 (2.8) 6.5 (3.4) 7.9 (2.1) Radiographic stage (III + IV), n (%) 40 (93.0) 5 (71.4) 6 (100.0) BCG vaccination, n (%) 41 (95.3) 6 (85.7) 6 (100.0) RF-IgM positivity, n (%) 36 (83.7) 6 (85.7) 6 (100.0) RF-IgM titre, IU/ml 323 (636) 313 (307) 292 (212) CRP, mg/dl 2.7 (2.2) 3.0 (2.9) 3.5 (3.5) Baseline DAS (0.99) 6.90 (0.83) 6.33 (1.06) Daily steroid dose, mg 6.3 (1.4) 6.8 (1.2) 6.5 (1.7) Used MTX, n (%) 42 (97.7) 7 (100) 6 (100) TNF-a inhibitors, n (%) Etanercept 22 (51.2) 4 (57.1) 2 (33.3) Adalimumab 21 (48.8) 3 (42.9) 4 (66.7) Frequency of comorbidities, n (%) Diabetes mellitus 3 (7.0) 0 (0.0) 1 (16.7) Anaemia (<9.0 gm/dl) 8 (18.6) 1 (14.3) 1 (16.7) Values are mean (S.D.) or number (%) of patients. BCG: Bacillus Calmette Guérin. circulating CD3 + T cells after 1 year of rituximab therapy in RA patients of different M. tuberculosis infection status (Fig. 2B). Ex vivo effects of rituximab on released IFN-g levels in the QFT-GIT assay As illustrated in Fig. 3A and 3B, IFN-g production was not inhibited by rituximab at concentrations of mg/ml in RA patients with QFT-GIT-positive results or patients with active TB. There was no significant difference in the percentage of inhibition of TB antigen-stimulated IFN-g production between QFT-GIT-positive patients and active TB patients (Fig. 3C). Association of the degree of B-cell depletion with the decrease in RF titres, DAS28 and IFN-g levels in RA patients undergoing rituximab therapy The degree of B-cell depletion after rituximab therapy was positively correlated with the decrease in RF titres (r = 0.305, P < 0.05) and the decrease in DAS28 (r = 0.264, P = 0.055). However, there was no significant correlation between the degree of B-cell depletion and the change of released IFN-g levels in the QFT-GIT assay. Discussion Consistent with the safety profile of rituximab therapy in clinical trials and cases reports [14 18], our results showed that no patients developed active TB among the 56 RA patients who received 1 year of rituximab therapy, including six patients with anti-tnf-associated TB. Based on these observations, we hypothesized that rituximab treatment would not increase the risk of active TB disease. To test this hypothesis, we conducted the present study, which, to the best of our knowledge, is the first attempt to investigate the effects of rituximab therapy on the released IFN-g levels in the QFT-GIT assay in RA patients of different M. tuberculosis infection status. Our results showed no significant change in the released IFN-g levels or QFT-GIT conversion in RA patients with LTBI or in those with anti-tnf-associated TB. Moreover, rituximab did not inhibit TB antigen-stimulated IFN-g production ex vivo in the present study. Given that IFN-g has a protective role against M. tuberculosis infection [10, 11], our results provide evidence of the safety of rituximab treatment against TB infection and offers supporting evidence for the clinical use of rituximab in RA patients with anti-tnf-associated TB. However, the impact of rituximab therapy on TB risk must be evaluated against the background of increased TB prevalence due to RA itself [1] and regional differences in exposure to M. tuberculosis. It is interesting to note that our results showed no significant change in the proportions of circulating CD3 + T cells among RA patients after 1 year of rituximab. Given that T-cell-mediated immunity plays a critical role in the optimal containment of M. tuberculosis [9, 10], little change in circulating T cells from our RA patients may partly explain the lack of significant change in the released IFN-g levels in the QFT-GIT assay. These observations provide evidence supporting the safety profile of rituximab therapy in our RA patients with LTBI or anti-tnfassociated TB. IFN-g response might predict the development of active TB in LTBI-positive subjects [29], with higher rates of progression to active TB in interferon-g release 700
5 Rituximab effect on released IFN-c levels in RA FIG. 2Released IFN-g levels, circulating immune cells and RA disease activity before and after rituximab therapy. The change in IFN-g released levels in the QFT-GIT assay (A), the percentages of circulating T cells (B) as well as B cells (C), serum levels of RF (D), DAS28 (E) and CRP levels (F) before and after 1 year of rituximab therapy for RA patients without LTBI, with LTBI and with anti-tnf-associated TB (recent TB) and the completion of anti-tubercular therapy (post-c/t). Data are presented as mean (S.E.M.). *P < 0.05, **P < 0.001, vs values before rituximab therapy, determined by the Wilcoxon signed rank test. assay-positive patients [30]. Although Hatemi et al. [31] demonstrated that short-term [3.6 (0.2) months] anti-tnf-a treatment did not cause a significant change in IFN-g response to TB-specific antigens, the results of previous studies showed that TNF-a inhibitors could suppress IFN-g production [28, 32]. In the present study, no significant change in the released IFN-g levels was observed in RA patients who had received 1 year of rituximab therapy. Moreover, our results showed that rituximab did not inhibit TB antigen-stimulated IFN-g production. This discrepancy in the change of released IFN-g levels between TNF-a inhibitors and rituximab therapy may explain the different risk of developing active TB for RA patients receiving different biologics. However, the sample size of our enrolled RA patients undergoing rituximab therapy was too small and the follow-up duration was too short to draw a conclusion regarding active TB risk. There were some limitations in our study. The sample size of rituximab therapy for anti-tnf-associated TB was too small to draw a conclusion for the effects of rituximab 701
6 Yi-Ming Chen et al. FIG. 3M. tuberculosis antigen-stimulated IFN-g production in whole-blood samples treated with serial concentrations of rituximab. Whole-blood samples from eight RA patients with QFT-GIT-positive results (A) and five patients with active TB (B) were incubated with or without rituximab. IFN-g production was shown as a percentage compared with control (without rituximab). The data are presented as median and the 25th percentile (lower bar) to the 75th percentile (upper bar) for each group. (C) Comparison of M. tuberculosis antigen-stimulated IFN-g production in whole-blood samples treated with rituximab 1 mg/ml between QFT-GIT-positive patients and active TB patients. The data are presented as box-plot diagrams, with the box encompassing the range of levels from the 25th percentile (lower bar) to the 75th percentile (upper bar). The horizontal line within the box indicates the median value and the horizontal lines above and below the box represent the maximum and minimum values, respectively, for each group. therapy on QFT-GIT assays. However, there are no case series in the literature of rituximab therapy in RA patients with anti-tnf-associated TB. Although the follow-up period was short (12 months), the data from a national registry indicate that the majority of clinically relevant infections occur within 7 months of the first infusion of rituximab [33], and 1 year was a sufficient duration to observe LTBI reactivation in RA patients receiving anti-tnf-a therapy [8]. However, our results should be interpreted with caution until longer follow-up data are available. In addition, the patients enrolled in this study were not an anti-tnf-a-naïve RA population, and thus our results might not be directly applicable to early or anti-tnf-a-naïve RA patients. Therefore a long-term study enrolling a larger group of patients, including an additional early RA population or a control RA group using non-biologic anti-rheumatic drugs alone, is required to validate our findings. In conclusion, the present study demonstrated that 1 year of rituximab therapy in RA patients was relatively safe compared with anti-tnf-a therapy regarding the risk of TB infection. Our results also showed no significant effect of rituximab therapy on the levels of released IFN-g in the QFT-GIT assay in RA patients, especially in those with LTBI or with anti-tnf-associated TB. This finding is of clinical importance, since a significant suppression of the proportion of T cells and IFN-g production would predispose patients to an increased susceptibility to M. tuberculosis infection [9, 10, 34]. Although the sample size was too small to obtain a definitive conclusion, our data suggest that rituximab therapy may be an alternative therapeutic option for RA patients with anti-tnfassociated TB. However, emerging evidence shows that B cells might play a role in optimizing the host defence against M. tuberculosis infection [19 21], so it is still necessary to assess and monitor the development of active TB in RA patients receiving rituximab therapy, particularly in those who had previously received TNF-a inhibitors. Rheumatology key messages. No significant effect of rituximab therapy on IFN-g released levels was observed in RA patients.. Rituximab may be an alternative therapeutic agent for RA patients with LTBI or anti-tnf-associated TB. Funding: This study was supported by grant NSC B-075 A-001-MY3 from the National Science Council, Taiwan. Disclosure statement: The authors have declared no conflicts of interest. References 1 Carmona L, Hernandez-Garcia C, Vadillo C et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30: Gomez-Reino JJ, Carmona L, Valverde VR et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:
7 Rituximab effect on released IFN-c levels in RA 3 Gardam MA, Keystone EC, Menzies R et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005;44: Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61: Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-tnf agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10: Chen DY, Shen GH, Chen YM et al. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFa inhibitors: the utility of IFNg assay. Ann Rheum Dis 2012;71: Boom WH. The role of T-cell subsets in Mycobacterium tuberculosis infection. Infect Agents Dis 1996;5: Barnes PF, Wizel B. Type 1 cytokines and the pathogenesis of tuberculosis. Am J Respir Crit Care Med 2000;161: Jurado JO, Pasquinelli V, Alvarez IB et al. IL-17 and IFN-g expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J Leukoc Biol 2012;91: Mohan VP, Scanga CA, Yu K et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69: Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy. Arthritis Rheum 2006;54: Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomised, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54: Mohrbacher A. B cell non-hodgkin s lymphoma: rituximab safety experience. Arthritis Res Ther 2005;7(Suppl 3): S Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350: Burr ML, Malaviya AP, Gaston JH, Carmichael AJ, Östör AJK. Rituximab in rheumatoid arthritis following anti-tnf-associated tuberculosis. Rheumatology 2008; 47: Jung N, Owczarczyk K, Hellmann M et al. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology 2008;47: Kevin L, Winthrop S, Yamashita S, Beekmann E, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis 2008;46: Ulrichs T, Kosmiadi GA, Trusov V et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004;204: Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007;178: Smolen JS, Keystone EC, Emery P et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: Hsieh PR, Liu YC, So J et al. Mycobacterium tuberculosis in Taiwan. J Infect 2006;52: Prevoo MLL, van t Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38: Van Gestel AM, Prevoo ML, van t Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39: American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161: Ogata A, Mori M, Hashimoto S et al. Minimal influence of tocilizumab on IFN-g synthesis by tuberculosis antigens. Mod Rheumatol 2010;20: Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007;13: Diel R, Loddenkemper R, Meywald-Walter K et al. Predictive value of a whole-blood IFN-{gamma} assay for the development of active TB disease. Am J Respir Crit Care Med 2008;177: Hatemi G, Melikoglu M, Ozbakir F et al. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 2012;14: R Hamdi H, Mariette X, Godot V et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumor necrosis factor antagonsits. Arthritis Res Ther 2006;8: R
8 Yi-Ming Chen et al. 33 Tony HP, Burmester G, Schulze-Koops H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13:R Caccamo N, Guggino G, Joosten SA et al. Multifunctional CD4 (+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010;40:
Tuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationPathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
1 Pathogenesis of Rheumatoid Arthritis 2 Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi:10.1038/nrrheum 2012.23 Biologic therapies used in the treatment of rheumatoid arthritis 3 Etanercept Infliximab
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationTNF-alpha antagonist therapy modify the tuberculin skin test response
DOI 10.1007/s00296-010-1424-3 ORIGINAL ARTICLE TNF-alpha antagonist therapy modify the tuberculin skin test response Tulin Cagatay Zeki Kilicaslan Penbe Cagatay Munevver Mertsoylu Ziya Gulbaran Reyhan
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More information(2) 83.3% b/w TST and T-SPOT, (2) 77.4% b/w TST and T-SPOT. 77.7% b/w TST and QFT-GIT. QFT-GIT, 22.2% in T-SPOT. TSPOT vs. TST (> 5 mm) vs.
Supplementary Table 1. Study characteristics of the included literature Low to moderate TB endemic region Shovman et al. (2009) [21] Minguez et al. (2012) [16], type 35 RA 35 RA 53 Patients with s (RA
More informationElevated risk of tuberculosis in patients with rheumatoid arthritis in Japan
ARD Online First, published on July 12, 2006 as 10.1136/ard.2005.047274 Concise report Elevated risk of tuberculosis in patients with rheumatoid arthritis in Japan Toru Yamada, Ayako Nakajima, Eisuke Inoue,
More informationIdentification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-tnf-α agents
Clinical research Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-tnf-α agents Jolanta Paluch-Oleś 1, Agnieszka Magryś 1, Maria Kozioł-Montewka
More informationA Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationKJLM. Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents
Korean J Lab Med 2011;31:271-278 Original Article Diagnostic Immunology KJLM Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTuberculosis and TNF Inhibitors
Tuberculosis and TNF Inhibitors Sundari Mase MD, MPH Medical Team Lead CDC/DTBE/FSEB January 18, 2011 Objectives Discuss the association between and epidemiology of TNF inhibitors and TB Discuss the challenges
More informationLatent tuberculosis (TB) infection (LTBI), a
COMMENTARY Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting Marisa Kardos, BS, and Alexa Boer Kimball, MD,
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationRESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS
Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai
More informationDelayed response to anti-tuberculosis treatment in a patient on infliximab
Respiratory Medicine (2005) 99, 648 652 CASE REPORT Delayed response to anti-tuberculosis treatment in a patient on infliximab Elina Vlachaki a, Kostas Psathakis a,, Kostas Tsintiris a, Alexios Iliopoulos
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationAppendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months
Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview Study Name Year Reference ABATACEPT (n=7) Moreland 2002 Moreland LW, Alten R, Van den Bosch
More informationORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationDetecting latent tuberculosis infection during anti-tumour necrosis factor therapy
Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy J.S. Ringrose 1, S.E. Sanche 2, R.M. Taylor-Gjevre 3 1 Division of General Internal Medicine, Department of Medicine,
More informationMædica - a Journal of Clinical Medicine
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #274: Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy National Quality Strategy Domain: Effective Clinical Care
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationClinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
Eur Respir J 2007; 30: 945 950 DOI: 10.1183/09031936.00040007 CopyrightßERS Journals Ltd 2007 Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase,
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationA Case of Tuberculous Arthritis Following the Use of Etanercept
CASE REPORT DOI: 10.3904/kjim.2009.24.4.397 A Case of Tuberculous Arthritis Following the Use of Etanercept Seung Won Choi 1, Jong Joon Ahn 1, Young Tae Hwang 1, Sang Hoon Koh 2, and Sung Do Cho 2 Departments
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationABSTRACT. Original Article Respiratory Diseases
J Korean Med Sci. 2018 Nov 19;33(47):e292 eissn 1598-6357 pissn 1011-8934 Original Article Respiratory Diseases Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment
More informationDiagnosis and Treatment of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists in Korea
J Korean Med Sci 2007; 22: 779-83 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Diagnosis and Treatment of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationComparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation
American Journal of Transplantation 2007; 7: 2797 2801 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationAnnual European Congress of Rheumatology (EULAR) Madrid, Spain, June 2017
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW DATA SUGGEST NO INCREASED CANCER RISK FOR RA PATIENTS PRESCRIBED BIOLOGICAL DMARDS Reassuring findings may positively
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationRepeated tuberculin skin testing following therapy with TNF-alpha inhibitors
Clin Rheumatol (2009) 28:167 172 DOI 10.1007/s10067-008-1007-9 ORIGINAL ARTICLE Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors Inbal Fuchs & Lone Avnon & Tamar Freud & Mahmoud
More informationLiterature Overview. Health Economics. Experience with QuantiFERON -TB Gold. Cellestis Clinical Guide series
Literature Overview Experience with QuantiFERON -TB Gold Health Economics Cellestis Clinical Guide series 2008 www.cellestis.com This literature overview is intended to provide healthcare professionals
More informationCase reports. Patient 1
REVIEW ARTICLE BJD British Journal of Dermatology Tuberculosis and tumour necrosis factor-a inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationComparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense
More informationJCM Version 3. Utilization of the QuantiFERON-TB Gold Test in a 2-Step Process with the
JCM Accepts, published online ahead of print on 23 June 2010 J. Clin. Microbiol. doi:10.1128/jcm.02253-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationUtility of PPD or IGRA to answer the age old question of "TB or not TB
Utility of PPD or IGRA to answer the age old question of "TB or not TB Thomas S. Alexander, Ph.D., D(ABMLI) Immunologist Summa Health alexandt@summahealth.org Yes, The reservation is in the name of Dr.
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationJennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN Phase Symposium: May 6, 2009 Background & Rationale Maryland
More informationClinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*
CHEST Clinical Utility of the QuantiFERON -2G Test for Elderly Patients With Active Tuberculosis* Yoshihiro Kobashi, MD, PhD; Keiji Mouri, MD; Shinich Yagi, MD; Yasushi Obase, MD, PhD; Naoyuki Miyashita,
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationEvaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2004, p. 1089 1093 Vol. 11, No. 6 1071-412X/04/$08.00 0 DOI: 10.1128/CDLI.11.6.1089 1093.2004 Copyright 2004, American Society for Microbiology. All
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationFactors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis
http://dx.doi.org/10.4046/trd.2012.72.5.416 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2012;72:416-425 CopyrightC2012. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationSynoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22
DC IL12, IL23 chemokines, ECM, Co-stimulation IL17, IL22 IFNγ ± Macrophage peptidoglycan lipopolysaccharide heat shock proteins Th1/Th17 IL17 IL22 Cell contact, co-stimulation immune complexes acute phase
More information[DOI] /j.issn
56 2018 1 1431 - [ ]- - T- SPOT.TB 5638 18T-SPOT.TB T-SPOT.TB86.5%(95%CI 71.2%~95.5%) 100%(95%CI 90.5%~100%) 52.9%(95%CI 27.8%~77.0%) 35.3%(95%CI 14.2%~61.7%) 80.0%(95%CI 64.4%~90.9%) 77.1%(95%CI 62.7%~88.0%)
More information6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline
Summary of Published Switch data Table 1. Information Patients Switch from (n) Reason for switch Switch to: (n) Results Numbers Presse Med. 2002 (1) 14 Infliximab (8) (6) 6 ADRs, 2 LOE 2 ADRs, 4 LOE (8)
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationJournal of Infectious Diseases Advance Access published August 2, 2013
Journal of Infectious Diseases Advance Access published August 2, 2013 1 Reversion and Conversion of Interferon-gamma Release Assay Results in HIV-1 Infected Individuals Maximilian C. Aichelburg 1,*, Thomas
More informationLife Threatening Intra-abdominal Sepsis in Patients on anti-tnfα Therapy.
Gut Online First, published on November 18, 2005 as 10.1136/gut.2005.085449 Life Threatening Intra-abdominal Sepsis in Patients on anti-tnfα Therapy. S Goode 1, G Tierney 2, C Deighton 3 1 Department of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
More informationPharmacy Medical Necessity Guidelines: Actemra (tocilizumab)
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or Medical
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationTable 9. Policy for Tuberculosis Surveillance and Screening
Policy for Tuberculosis Surveillance and Screening Purpose: to identify active cases of tuberculosis or latent TB among residents and staff of the nursing home in order to prevent transmission in this
More informationTuberculosis Prophylaxis and Biologics Treatment for Rheumatoid Arthritis
NORTHERN (HIGH)LIGHTS Tuberculosis Prophylaxis and Biologics Treatment for Rheumatoid Arthritis By Nicholas M. Baniak, BSc; Vernon M. Hoeppner, MD, FRCPC; and Wojciech P. Olszynski, MD, PhD, FRCPC, CCD
More informationTofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients
doi: 10.2169/internalmedicine.9341-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationIn our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between
In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between the two, we also propose a classification system for
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationI n the past, analgesics and nonsteroidal
Rituximab in advanced rheumatoid arthritis Michael Guida BSc, MA Rheumatoid arthritis (RA) continues to have a major impact on public health. Costs to the individual and to the NHS are high, and treatment
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationMETHODS In the context of an indirect comparison metaanalysis between tocilizumab and other biological
c Additional data are published online only at http://ard.bmj. com/content/vol69/issue1 Correspondence to: Professor M Boers, Department of Epidemiology and Biostatistics, VU University Medical Centre,
More informationPrevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia
RESEARCH ARTICLE Open Access Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia Shaharudin Rafiza 1*, Krishna Gopal Rampal 2, Aris Tahir 3 Abstract Background:
More informationQualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationValidity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients
ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More informationPREVENTING TB IN PATIENTS WITH CROHN S DISEASE NEEDING INFLIXIMAB OR OTHER ANTI-TNF THERAPY
Gut Online First, published on August 19, 2005 as 10.1136/gut.2005.076034 PREVENTING TB IN PATIENTS WITH CROHN S DISEASE NEEDING INFLIXIMAB OR OTHER ANTI-TNF THERAPY DS Rampton Centre for Gastroenterology,
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More information